Thalidomide (α-N-[phthalimido] glutarimide, C13 H10 N2 O4), is a glutamic acid derivative initially introduced as a sedative hypnotic nearly forty years ago. It was withdrawn following numerous reports linking it to a characteristic pattern of congenital abnormalities in babies born to mothers who used the drug for morning sickness. It has gradually been re-introduced into clinical practice over the past two decades, albeit under strict regulation, since it was found to be broad spectrum of anti-cancer activity. Anti-tumor activity of thalidomide may be related to a number of known properties, including anti-tumor necrosis factor (TNF)-α and T-cell co-stimulatory and anti-angiogenic activities. Nanoemulsions of thalidomide were prepared in the form of intravenous injection for the treatment of cancer. The therapeutic potential of thalidomide provided motivation to develop more effective derivatives with considerably reduced toxicity. There are two types of thalidomide's immunomodulatory (IMiDs) analogs are lenalidomide and pomalidomide represent a novel class of compounds with numerous effects on the immune system. These analogs are thought to mediate the anticancer and anti-inflammatory effects observed in humans. Thalidomide is currently approved for the treatment of dermal reaction to leprosy and is currently in phase III trials for multiple myeloma (MM). IMiDs inhibit the cytokine's tumor necrosis factor-α (TNF-α), interleukins (IL) 1 α, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). The repression of the tumor necrosis factor-a (TNF-a) expression is the crucial factor of many of the anti-inflammatory properties of thalidomide.
Tuberculosis (TB) stays one of the deadliest irresistible ailments in charge of millions of passing's every year over the world. In this paper we present a general review of TB including the pathogenes rules. In readiness of this review, we scanned PubMed for pertinent articles on TB. Furthermore, we looked through the sites of global establishments like the World Health Organization (WHO) and the US Centers for Disease contro and Prevention (CDC) for related reports and clinical rules. This paper has been composed with the goal to offer general training to wellbeing experts, arrangement producers, patients and the general population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.